| 000 | 01324 a2200361 4500 | ||
|---|---|---|---|
| 005 | 20250514061838.0 | ||
| 264 | 0 | _c20030828 | |
| 008 | 200308s 0 0 ger d | ||
| 022 | _a0028-2804 | ||
| 024 | 7 |
_a10.1007/s00115-003-1481-x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGerlach, M | |
| 245 | 0 | 0 |
_a[Current preclinical findings on substances against Parkinson's disease]. _h[electronic resource] |
| 260 |
_bDer Nervenarzt _cMar 2003 |
||
| 300 |
_aS2-6 p. _bdigital |
||
| 500 | _aPublication Type: English Abstract; Journal Article | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntiparkinson Agents _xadverse effects |
| 650 | 0 | 4 | _aCaenorhabditis elegans |
| 650 | 0 | 4 |
_aCorpus Striatum _xdrug effects |
| 650 | 0 | 4 |
_aDopamine Agonists _xadverse effects |
| 650 | 0 | 4 | _aDrug Evaluation, Preclinical |
| 650 | 0 | 4 |
_aDrugs, Investigational _xadverse effects |
| 650 | 0 | 4 |
_aDyskinesia, Drug-Induced _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLevodopa _xadverse effects |
| 650 | 0 | 4 |
_aNeuroprotective Agents _xadverse effects |
| 650 | 0 | 4 |
_aParkinson Disease _xdrug therapy |
| 650 | 0 | 4 |
_aParkinsonian Disorders _xdrug therapy |
| 700 | 1 | _aRiederer, P | |
| 773 | 0 |
_tDer Nervenarzt _gvol. 74 Suppl 1 _gp. S2-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00115-003-1481-x _zAvailable from publisher's website |
| 999 |
_c12419905 _d12419905 |
||